GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Notes Receivable

TECX (Tectonic Therapeutic) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Notes Receivable?

Tectonic Therapeutic's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Tectonic Therapeutic Notes Receivable Historical Data

The historical data trend for Tectonic Therapeutic's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Notes Receivable Chart

Tectonic Therapeutic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Tectonic Therapeutic Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tectonic Therapeutic Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Tectonic Therapeutic Notes Receivable Related Terms

Thank you for viewing the detailed overview of Tectonic Therapeutic's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Tectonic Therapeutic Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.